Eric Haura
Associate Center Director, Clinical Science Moffitt Cancer Center
Seminars
Wednesday 17th September 2025
Panel Discussion: Reducing Non-Responsiveness of RAS-Targeted Therapies by Delving into Mutation & Tissue Specific Impacts to Improve Drug Efficacy
1:00 pm
- Â Uncovering the current status and unmet medical needs for patients with RAS-driven cancers, what cancers need more improved response rates?
- What genomic features predict poor response and outcomes for RAS-targeting therapies?
- How do you successfully overcome or delay resistance to RAS-targeting therapies?
Wednesday 17th September 2025
Developing Multi-Omic Biomarker Strategies for Assessing Sensitivity of RASTargeting Drugs for More Efficacious Therapies
11:00 am
- Uncovering the impact of genomics on RAS inhibitor sensitivity
- Highlighting how transcriptional signatures may affect sensitivity to RAS targeting drugs
- Predicting RAS sensitivity through proteomic biomarkers and pathway analysis to advance more effective RAS-targeting drugs and combinations
